 Sarah Parker
Concepts (332)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antimicrobial Stewardship | 11 | 2021 | 119 | 4.700 |
Why?
| | Hospitals, Pediatric | 22 | 2022 | 516 | 3.660 |
Why?
| | Anti-Infective Agents | 12 | 2021 | 239 | 3.490 |
Why?
| | Anti-Bacterial Agents | 34 | 2024 | 1818 | 3.140 |
Why?
| | Bacteremia | 4 | 2025 | 214 | 2.180 |
Why?
| | Osteomyelitis | 9 | 2024 | 139 | 2.110 |
Why?
| | Arthritis, Infectious | 7 | 2022 | 69 | 1.950 |
Why?
| | Drug Utilization Review | 6 | 2020 | 58 | 1.620 |
Why?
| | Bacterial Infections | 7 | 2025 | 245 | 1.440 |
Why?
| | Blood Culture | 4 | 2025 | 23 | 1.430 |
Why?
| | Metronidazole | 3 | 2019 | 20 | 1.230 |
Why?
| | Appendicitis | 3 | 2019 | 139 | 1.110 |
Why?
| | Otitis Media | 4 | 2024 | 167 | 1.050 |
Why?
| | Child | 49 | 2025 | 21921 | 1.050 |
Why?
| | Staphylococcal Infections | 5 | 2025 | 387 | 1.030 |
Why?
| | Acute Disease | 8 | 2025 | 994 | 0.960 |
Why?
| | Kingella kingae | 2 | 2022 | 12 | 0.880 |
Why?
| | Intensive Care Units, Neonatal | 2 | 2025 | 258 | 0.870 |
Why?
| | Retrospective Studies | 27 | 2025 | 15909 | 0.750 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 3 | 2025 | 236 | 0.720 |
Why?
| | Musculoskeletal System | 1 | 2022 | 49 | 0.710 |
Why?
| | Musculoskeletal Diseases | 2 | 2025 | 83 | 0.710 |
Why?
| | Respiration, Artificial | 2 | 2022 | 670 | 0.680 |
Why?
| | Surgical Wound Infection | 2 | 2022 | 313 | 0.670 |
Why?
| | Humans | 73 | 2025 | 138651 | 0.600 |
Why?
| | Infant | 21 | 2025 | 9574 | 0.580 |
Why?
| | Respiratory Tract Infections | 1 | 2022 | 383 | 0.560 |
Why?
| | Interdisciplinary Communication | 1 | 2019 | 191 | 0.560 |
Why?
| | Drug Resistance, Bacterial | 3 | 2021 | 184 | 0.550 |
Why?
| | Medical Order Entry Systems | 1 | 2018 | 43 | 0.540 |
Why?
| | Cefoxitin | 1 | 2017 | 7 | 0.530 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 2017 | 47 | 0.530 |
Why?
| | Microbial Sensitivity Tests | 5 | 2024 | 351 | 0.530 |
Why?
| | Ceftriaxone | 1 | 2017 | 20 | 0.520 |
Why?
| | Cephalosporins | 2 | 2015 | 45 | 0.520 |
Why?
| | beta-Lactams | 1 | 2017 | 32 | 0.510 |
Why?
| | Child, Preschool | 18 | 2025 | 11158 | 0.510 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2017 | 69 | 0.510 |
Why?
| | Drug Costs | 1 | 2017 | 110 | 0.510 |
Why?
| | Interprofessional Relations | 1 | 2019 | 290 | 0.500 |
Why?
| | Pneumonia, Bacterial | 1 | 2017 | 114 | 0.500 |
Why?
| | Prescriptions | 1 | 2016 | 73 | 0.500 |
Why?
| | Pyomyositis | 3 | 2022 | 15 | 0.500 |
Why?
| | Communicable Diseases | 4 | 2021 | 161 | 0.480 |
Why?
| | Exanthema | 1 | 2016 | 80 | 0.470 |
Why?
| | Neutropenia | 1 | 2016 | 157 | 0.470 |
Why?
| | Mycobacterium tuberculosis | 4 | 2021 | 315 | 0.460 |
Why?
| | Diarrhea | 1 | 2016 | 183 | 0.460 |
Why?
| | Thimerosal | 2 | 2005 | 6 | 0.450 |
Why?
| | Health Resources | 1 | 2016 | 128 | 0.440 |
Why?
| | Inpatients | 4 | 2021 | 502 | 0.440 |
Why?
| | Preservatives, Pharmaceutical | 2 | 2005 | 26 | 0.440 |
Why?
| | Enterovirus D, Human | 1 | 2016 | 85 | 0.430 |
Why?
| | Decision Support Systems, Clinical | 1 | 2018 | 253 | 0.420 |
Why?
| | Disease Outbreaks | 2 | 2021 | 416 | 0.410 |
Why?
| | Electronic Health Records | 2 | 2019 | 1092 | 0.410 |
Why?
| | Cephalexin | 2 | 2024 | 11 | 0.400 |
Why?
| | Enterovirus Infections | 1 | 2016 | 172 | 0.400 |
Why?
| | Inappropriate Prescribing | 1 | 2013 | 57 | 0.400 |
Why?
| | Guideline Adherence | 1 | 2017 | 559 | 0.390 |
Why?
| | Pandemics | 2 | 2022 | 1641 | 0.390 |
Why?
| | Cross Infection | 3 | 2025 | 249 | 0.380 |
Why?
| | Intensive Care Units, Pediatric | 3 | 2025 | 262 | 0.360 |
Why?
| | Referral and Consultation | 1 | 2017 | 793 | 0.350 |
Why?
| | Health Personnel | 1 | 2018 | 732 | 0.350 |
Why?
| | Vancomycin | 2 | 2023 | 82 | 0.340 |
Why?
| | Liver Abscess, Amebic | 2 | 2009 | 3 | 0.320 |
Why?
| | Phospholipases A | 2 | 2007 | 104 | 0.310 |
Why?
| | Urinary Tract Infections | 2 | 2025 | 193 | 0.310 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1567 | 0.300 |
Why?
| | Stomach Rupture | 1 | 2009 | 3 | 0.300 |
Why?
| | Phospholipases | 1 | 2009 | 14 | 0.300 |
Why?
| | Male | 27 | 2025 | 68260 | 0.300 |
Why?
| | Thiolester Hydrolases | 1 | 2009 | 13 | 0.300 |
Why?
| | Pericardial Effusion | 1 | 2009 | 21 | 0.300 |
Why?
| | Staphylococcus aureus | 5 | 2024 | 433 | 0.290 |
Why?
| | Lactones | 1 | 2009 | 58 | 0.290 |
Why?
| | Pleural Effusion | 1 | 2009 | 57 | 0.290 |
Why?
| | Peritonitis | 1 | 2009 | 86 | 0.280 |
Why?
| | Diphtheria-Tetanus-Pertussis Vaccine | 2 | 2005 | 27 | 0.280 |
Why?
| | Colorado | 4 | 2020 | 4555 | 0.280 |
Why?
| | Drug Utilization | 3 | 2017 | 167 | 0.280 |
Why?
| | Carboxylic Ester Hydrolases | 1 | 2007 | 20 | 0.270 |
Why?
| | Cefadroxil | 2 | 2024 | 8 | 0.260 |
Why?
| | Gene Expression Regulation, Bacterial | 2 | 2009 | 318 | 0.260 |
Why?
| | Female | 24 | 2025 | 73763 | 0.260 |
Why?
| | Cost Savings | 2 | 2017 | 84 | 0.260 |
Why?
| | Time Factors | 4 | 2024 | 6851 | 0.260 |
Why?
| | Dermatomycoses | 1 | 2006 | 8 | 0.250 |
Why?
| | Infant, Newborn | 7 | 2025 | 6144 | 0.250 |
Why?
| | Adolescent | 15 | 2025 | 21564 | 0.240 |
Why?
| | Pharmacy Service, Hospital | 2 | 2017 | 87 | 0.240 |
Why?
| | Drug Approval | 1 | 2006 | 91 | 0.240 |
Why?
| | Mycobacterium | 1 | 2007 | 110 | 0.240 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2006 | 127 | 0.230 |
Why?
| | Infection Control | 3 | 2015 | 165 | 0.230 |
Why?
| | Intellectual Property | 1 | 2005 | 7 | 0.230 |
Why?
| | Autistic Disorder | 2 | 2005 | 206 | 0.230 |
Why?
| | Measles | 1 | 2025 | 45 | 0.220 |
Why?
| | Mycoses | 1 | 2025 | 83 | 0.220 |
Why?
| | Bacterial Proteins | 2 | 2018 | 892 | 0.220 |
Why?
| | Simplexvirus | 1 | 2004 | 82 | 0.220 |
Why?
| | Encephalitis, Viral | 1 | 2004 | 45 | 0.210 |
Why?
| | Herpes Simplex | 1 | 2004 | 95 | 0.210 |
Why?
| | Amoxicillin | 1 | 2024 | 35 | 0.210 |
Why?
| | Hospitalization | 5 | 2023 | 2235 | 0.200 |
Why?
| | Lymphadenitis | 1 | 2023 | 6 | 0.200 |
Why?
| | Extracellular Vesicles | 1 | 2025 | 148 | 0.200 |
Why?
| | Drug Administration Schedule | 3 | 2017 | 768 | 0.200 |
Why?
| | Drainage | 2 | 2017 | 173 | 0.200 |
Why?
| | Cisplatin | 1 | 2024 | 327 | 0.190 |
Why?
| | Machine Learning | 2 | 2025 | 517 | 0.190 |
Why?
| | Databases, Factual | 4 | 2025 | 1415 | 0.190 |
Why?
| | Exudates and Transudates | 1 | 2021 | 13 | 0.180 |
Why?
| | Cross-Over Studies | 1 | 2024 | 556 | 0.180 |
Why?
| | Immunotherapy | 1 | 2006 | 634 | 0.180 |
Why?
| | Fluoroquinolones | 1 | 2021 | 42 | 0.170 |
Why?
| | Risk Adjustment | 1 | 2021 | 81 | 0.170 |
Why?
| | Fever | 2 | 2017 | 305 | 0.170 |
Why?
| | Treatment Outcome | 7 | 2024 | 10923 | 0.170 |
Why?
| | Antibiotic Prophylaxis | 1 | 2022 | 121 | 0.170 |
Why?
| | Mucocutaneous Lymph Node Syndrome | 1 | 2021 | 91 | 0.170 |
Why?
| | Delayed Diagnosis | 1 | 2021 | 92 | 0.170 |
Why?
| | Bone Diseases, Infectious | 1 | 2020 | 8 | 0.170 |
Why?
| | Hospitals | 3 | 2021 | 695 | 0.170 |
Why?
| | Meningitis | 1 | 2021 | 81 | 0.160 |
Why?
| | Laboratories | 1 | 2021 | 108 | 0.160 |
Why?
| | Molecular Diagnostic Techniques | 2 | 2020 | 102 | 0.160 |
Why?
| | Trachea | 1 | 2021 | 255 | 0.160 |
Why?
| | Bacteroides fragilis | 1 | 2019 | 13 | 0.160 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2024 | 801 | 0.160 |
Why?
| | Encephalitis | 1 | 2021 | 136 | 0.150 |
Why?
| | Appendectomy | 2 | 2017 | 89 | 0.150 |
Why?
| | Monte Carlo Method | 1 | 2019 | 143 | 0.150 |
Why?
| | Pediatrics | 3 | 2017 | 1078 | 0.150 |
Why?
| | Antibodies, Monoclonal | 1 | 2006 | 1436 | 0.150 |
Why?
| | Neisseriaceae Infections | 1 | 2018 | 6 | 0.150 |
Why?
| | Autophagy | 1 | 2021 | 285 | 0.150 |
Why?
| | Area Under Curve | 1 | 2019 | 319 | 0.150 |
Why?
| | Entamoeba histolytica | 2 | 2009 | 10 | 0.150 |
Why?
| | Hospital Records | 1 | 2018 | 10 | 0.150 |
Why?
| | Reactive Oxygen Species | 1 | 2021 | 624 | 0.140 |
Why?
| | Proteomics | 1 | 2025 | 1110 | 0.140 |
Why?
| | Drug Therapy, Combination | 2 | 2021 | 1032 | 0.140 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2021 | 248 | 0.140 |
Why?
| | Medical Records Systems, Computerized | 1 | 2018 | 95 | 0.140 |
Why?
| | Tuberculosis | 1 | 2021 | 280 | 0.140 |
Why?
| | Hydrolysis | 2 | 2009 | 193 | 0.140 |
Why?
| | Patient Readmission | 3 | 2017 | 703 | 0.130 |
Why?
| | Sequence Homology, Amino Acid | 2 | 2009 | 391 | 0.130 |
Why?
| | Combined Modality Therapy | 2 | 2017 | 1235 | 0.130 |
Why?
| | Abdominal Abscess | 1 | 2017 | 25 | 0.130 |
Why?
| | Central Venous Catheters | 1 | 2017 | 51 | 0.130 |
Why?
| | Administration, Oral | 2 | 2016 | 788 | 0.130 |
Why?
| | Abscess | 1 | 2017 | 77 | 0.130 |
Why?
| | Drug Substitution | 1 | 2017 | 56 | 0.130 |
Why?
| | Medical Records | 1 | 2017 | 180 | 0.130 |
Why?
| | Drug Resistance | 1 | 2017 | 149 | 0.130 |
Why?
| | Communicable Disease Control | 1 | 2017 | 83 | 0.130 |
Why?
| | Rural Population | 1 | 2021 | 582 | 0.120 |
Why?
| | Pharmacists | 1 | 2019 | 260 | 0.120 |
Why?
| | Amino Acid Sequence | 4 | 2009 | 2155 | 0.120 |
Why?
| | Drug Prescriptions | 1 | 2018 | 259 | 0.120 |
Why?
| | Osteoarthritis | 1 | 2018 | 196 | 0.120 |
Why?
| | Molecular Sequence Data | 4 | 2009 | 2923 | 0.120 |
Why?
| | Sensitivity and Specificity | 3 | 2025 | 1941 | 0.120 |
Why?
| | Administration, Intravenous | 1 | 2016 | 156 | 0.120 |
Why?
| | Aftercare | 1 | 2017 | 215 | 0.120 |
Why?
| | Cell Wall | 2 | 2021 | 57 | 0.120 |
Why?
| | United States | 9 | 2025 | 14938 | 0.120 |
Why?
| | Length of Stay | 2 | 2020 | 1238 | 0.120 |
Why?
| | Community-Acquired Infections | 1 | 2017 | 173 | 0.120 |
Why?
| | Knowledge Management | 1 | 2014 | 2 | 0.110 |
Why?
| | Radiography | 1 | 2017 | 841 | 0.110 |
Why?
| | Clostridium Infections | 1 | 2015 | 73 | 0.110 |
Why?
| | Drug Monitoring | 1 | 2016 | 215 | 0.110 |
Why?
| | Prospective Studies | 3 | 2024 | 7554 | 0.110 |
Why?
| | Postoperative Care | 1 | 2016 | 274 | 0.110 |
Why?
| | Cost-Benefit Analysis | 1 | 2017 | 608 | 0.110 |
Why?
| | Antitubercular Agents | 2 | 2021 | 203 | 0.110 |
Why?
| | Medication Therapy Management | 1 | 2014 | 77 | 0.100 |
Why?
| | Acute Kidney Injury | 1 | 2021 | 812 | 0.100 |
Why?
| | Antineoplastic Agents | 1 | 2024 | 2152 | 0.100 |
Why?
| | Tomography, X-Ray Computed | 3 | 2009 | 2698 | 0.100 |
Why?
| | Ambulatory Care | 1 | 2017 | 575 | 0.100 |
Why?
| | Risk Assessment | 2 | 2016 | 3433 | 0.100 |
Why?
| | Laparoscopy | 1 | 2017 | 454 | 0.090 |
Why?
| | Quality of Health Care | 1 | 2017 | 654 | 0.090 |
Why?
| | Genotype | 3 | 2021 | 1842 | 0.090 |
Why?
| | Drug Hypersensitivity | 1 | 2013 | 95 | 0.090 |
Why?
| | Bacteria | 3 | 2023 | 867 | 0.090 |
Why?
| | Physicians | 1 | 2019 | 932 | 0.080 |
Why?
| | Cohort Studies | 2 | 2017 | 5697 | 0.080 |
Why?
| | Patient Education as Topic | 1 | 2014 | 766 | 0.080 |
Why?
| | Young Adult | 4 | 2021 | 13305 | 0.080 |
Why?
| | Attitude of Health Personnel | 1 | 2017 | 1157 | 0.080 |
Why?
| | Paromomycin | 1 | 2009 | 3 | 0.080 |
Why?
| | Mycolic Acids | 1 | 2009 | 7 | 0.080 |
Why?
| | Trophozoites | 1 | 2009 | 4 | 0.080 |
Why?
| | Practice Patterns, Physicians' | 1 | 2018 | 1323 | 0.080 |
Why?
| | Antiprotozoal Agents | 1 | 2009 | 16 | 0.070 |
Why?
| | DNA, Protozoan | 1 | 2008 | 32 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2017 | 2049 | 0.070 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2009 | 141 | 0.070 |
Why?
| | Nitrobenzenes | 1 | 2007 | 13 | 0.070 |
Why?
| | Chromatography, Thin Layer | 1 | 2007 | 27 | 0.070 |
Why?
| | Cell Line, Tumor | 2 | 2025 | 3392 | 0.070 |
Why?
| | Terminology as Topic | 1 | 2009 | 243 | 0.070 |
Why?
| | Polysorbates | 1 | 2007 | 41 | 0.070 |
Why?
| | Injections, Intravenous | 2 | 2017 | 202 | 0.060 |
Why?
| | Animals | 6 | 2024 | 37217 | 0.060 |
Why?
| | Membrane Lipids | 1 | 2007 | 91 | 0.060 |
Why?
| | Selection, Genetic | 1 | 2008 | 263 | 0.060 |
Why?
| | Maximum Tolerated Dose | 1 | 2006 | 204 | 0.060 |
Why?
| | Recombinant Proteins | 1 | 2009 | 1352 | 0.060 |
Why?
| | Measles Vaccine | 1 | 2025 | 20 | 0.060 |
Why?
| | Enzyme Inhibitors | 1 | 2009 | 847 | 0.060 |
Why?
| | United States Food and Drug Administration | 1 | 2006 | 205 | 0.060 |
Why?
| | Risk Factors | 2 | 2016 | 10252 | 0.060 |
Why?
| | Aminopeptidases | 1 | 2024 | 22 | 0.060 |
Why?
| | Ethylmercury Compounds | 1 | 2004 | 1 | 0.060 |
Why?
| | Diphtheria-Tetanus Vaccine | 1 | 2004 | 4 | 0.060 |
Why?
| | Methylmercury Compounds | 1 | 2004 | 8 | 0.060 |
Why?
| | Aphasia | 1 | 2004 | 22 | 0.060 |
Why?
| | Adult | 5 | 2021 | 38201 | 0.050 |
Why?
| | Mass Spectrometry | 2 | 2025 | 734 | 0.050 |
Why?
| | Diagnosis, Differential | 1 | 2009 | 1482 | 0.050 |
Why?
| | Patient Discharge | 2 | 2025 | 916 | 0.050 |
Why?
| | Escherichia coli | 1 | 2009 | 827 | 0.050 |
Why?
| | Half-Life | 1 | 2004 | 146 | 0.050 |
Why?
| | North America | 1 | 2025 | 304 | 0.050 |
Why?
| | Streptococcus pyogenes | 1 | 2004 | 38 | 0.050 |
Why?
| | Amoxicillin-Potassium Clavulanate Combination | 1 | 2024 | 16 | 0.050 |
Why?
| | Acyclovir | 1 | 2004 | 95 | 0.050 |
Why?
| | Hematologic Neoplasms | 1 | 2006 | 158 | 0.050 |
Why?
| | Child Development Disorders, Pervasive | 1 | 2004 | 62 | 0.050 |
Why?
| | Reproducibility of Results | 2 | 2023 | 3307 | 0.050 |
Why?
| | Vomiting | 1 | 2004 | 129 | 0.050 |
Why?
| | beta-Lactamases | 1 | 2024 | 49 | 0.050 |
Why?
| | Drug Industry | 1 | 2005 | 109 | 0.050 |
Why?
| | Kinetics | 1 | 2007 | 1645 | 0.050 |
Why?
| | Ampicillin | 1 | 2023 | 14 | 0.050 |
Why?
| | Nasopharynx | 1 | 2023 | 72 | 0.050 |
Why?
| | Haemophilus influenzae | 1 | 2023 | 63 | 0.050 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2023 | 53 | 0.050 |
Why?
| | Pneumonia | 1 | 2009 | 644 | 0.050 |
Why?
| | Cephalothin | 1 | 2022 | 5 | 0.050 |
Why?
| | Oxacillin | 1 | 2022 | 5 | 0.050 |
Why?
| | Type C Phospholipases | 1 | 2002 | 73 | 0.050 |
Why?
| | Methicillin | 1 | 2022 | 10 | 0.050 |
Why?
| | Cefazolin | 1 | 2022 | 20 | 0.050 |
Why?
| | Single-Cell Analysis | 1 | 2025 | 321 | 0.050 |
Why?
| | Butanes | 1 | 2021 | 4 | 0.050 |
Why?
| | Gestational Age | 1 | 2025 | 916 | 0.050 |
Why?
| | Cell Extracts | 1 | 2021 | 21 | 0.050 |
Why?
| | DNA Glycosylases | 1 | 2021 | 8 | 0.050 |
Why?
| | Ubiquinone | 1 | 2021 | 31 | 0.040 |
Why?
| | Developmental Disabilities | 1 | 2004 | 268 | 0.040 |
Why?
| | Streptococcus pneumoniae | 1 | 2023 | 169 | 0.040 |
Why?
| | Pyridinium Compounds | 1 | 2021 | 28 | 0.040 |
Why?
| | Autophagy-Related Proteins | 1 | 2021 | 46 | 0.040 |
Why?
| | Arkansas | 1 | 2021 | 18 | 0.040 |
Why?
| | Megakaryocytes | 1 | 2021 | 36 | 0.040 |
Why?
| | Microbiology | 1 | 2021 | 24 | 0.040 |
Why?
| | Reference Standards | 1 | 2021 | 184 | 0.040 |
Why?
| | Seizures | 1 | 2004 | 431 | 0.040 |
Why?
| | Organophosphorus Compounds | 1 | 2021 | 78 | 0.040 |
Why?
| | Staining and Labeling | 1 | 2021 | 153 | 0.040 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2021 | 155 | 0.040 |
Why?
| | Drug Combinations | 1 | 2021 | 346 | 0.040 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2021 | 174 | 0.040 |
Why?
| | Myositis | 1 | 2020 | 52 | 0.040 |
Why?
| | Pseudomonas aeruginosa | 1 | 2002 | 348 | 0.040 |
Why?
| | Neoplasms | 2 | 2025 | 2681 | 0.040 |
Why?
| | Coronary Vessels | 1 | 2021 | 247 | 0.040 |
Why?
| | Diagnostic Errors | 1 | 2020 | 174 | 0.040 |
Why?
| | Feces | 2 | 2015 | 486 | 0.040 |
Why?
| | Clindamycin | 1 | 2018 | 15 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2021 | 5520 | 0.040 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2024 | 1388 | 0.040 |
Why?
| | Developed Countries | 1 | 2018 | 39 | 0.040 |
Why?
| | Hospital Charges | 1 | 2018 | 45 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 1 | 2021 | 571 | 0.040 |
Why?
| | Methyltransferases | 1 | 2018 | 72 | 0.040 |
Why?
| | Bacteriological Techniques | 1 | 2018 | 67 | 0.040 |
Why?
| | Research Design | 1 | 2004 | 1118 | 0.030 |
Why?
| | Medical Staff, Hospital | 1 | 2018 | 82 | 0.030 |
Why?
| | Controlled Before-After Studies | 1 | 2017 | 14 | 0.030 |
Why?
| | Age Distribution | 1 | 2018 | 393 | 0.030 |
Why?
| | Sex Distribution | 1 | 2018 | 377 | 0.030 |
Why?
| | Metformin | 1 | 2021 | 331 | 0.030 |
Why?
| | Prostatic Neoplasms | 1 | 2025 | 1044 | 0.030 |
Why?
| | Blood Platelets | 1 | 2021 | 427 | 0.030 |
Why?
| | Arthritis, Rheumatoid | 1 | 2006 | 1164 | 0.030 |
Why?
| | Benchmarking | 1 | 2018 | 187 | 0.030 |
Why?
| | Mice | 2 | 2021 | 17814 | 0.030 |
Why?
| | Myocardium | 1 | 2021 | 921 | 0.030 |
Why?
| | Vaccination | 1 | 2025 | 1437 | 0.030 |
Why?
| | Comorbidity | 1 | 2021 | 1656 | 0.030 |
Why?
| | Genomics | 1 | 2021 | 796 | 0.030 |
Why?
| | Lung | 1 | 2009 | 4106 | 0.030 |
Why?
| | Early Diagnosis | 1 | 2016 | 239 | 0.030 |
Why?
| | Algorithms | 1 | 2023 | 1740 | 0.030 |
Why?
| | Recurrence | 1 | 2017 | 1084 | 0.030 |
Why?
| | Alcoholism | 1 | 2021 | 817 | 0.030 |
Why?
| | Asthma | 1 | 2006 | 1888 | 0.030 |
Why?
| | Inservice Training | 1 | 2014 | 122 | 0.030 |
Why?
| | Kidney | 1 | 2021 | 1466 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2021 | 2113 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2021 | 1992 | 0.030 |
Why?
| | Medical Oncology | 1 | 2015 | 304 | 0.020 |
Why?
| | Substrate Specificity | 2 | 2004 | 383 | 0.020 |
Why?
| | Brain | 1 | 2004 | 2792 | 0.020 |
Why?
| | Hypoglycemic Agents | 1 | 2021 | 1341 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2021 | 4315 | 0.020 |
Why?
| | Dysentery, Amebic | 1 | 2008 | 2 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2021 | 5803 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2015 | 3523 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2008 | 1047 | 0.010 |
Why?
| | Prophages | 1 | 2004 | 7 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2016 | 2722 | 0.010 |
Why?
| | Structure-Activity Relationship | 1 | 2004 | 575 | 0.010 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2002 | 144 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2002 | 336 | 0.010 |
Why?
| | Choline | 1 | 2002 | 131 | 0.010 |
Why?
| | Alleles | 1 | 2004 | 887 | 0.010 |
Why?
| | Hemolysis | 1 | 2002 | 202 | 0.010 |
Why?
| | Phospholipids | 1 | 2002 | 219 | 0.010 |
Why?
| | Base Sequence | 1 | 2004 | 2174 | 0.010 |
Why?
| | Calcium | 1 | 2002 | 1180 | 0.010 |
Why?
| | Aged | 1 | 2009 | 24024 | 0.000 |
Why?
| | Middle Aged | 1 | 2009 | 33604 | 0.000 |
Why?
|
|
Parker's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|